Antituberculous vaccine development: A perspective for the endemic world

Expert Review of Vaccines

Volumn 8, Issue 11, 2009, Pages 1547-1553

  Verma, Indu ^a   Grover, Ajay ^b  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

^b Department of Environmental and Radiological Health Sciences   (United States)

Author keywords

Bacillus Calmette Gu rin; Endemic world; TB; Tuberculosis; Vaccine

Indexed keywords

ADVAC VACCINE; AERAS 405 SHIGELLA VACCINE; AERAS 407 RBCG VACCINE; AG85 VACCINE; BCG VACCINE; HYBRID 1 VACCINE; HYVAC 4 VACCINE; MTB72F VACCINE; MVA85A VACCINE; MYCOBACTERIUM VACCAE VACCINE; PLACEBO; RBCG30 VACCINE; RBCG:DUREC HLY VACCINE; RECOMBINANT VACCINE; RUTI VACCINE; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

BACTERIAL STRAIN; CLINICAL TRIAL; HUMAN; MILIARY TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; TUBERCULOUS MENINGITIS;

ANIMALS; BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; ENDEMIC DISEASES; HUMANS; TUBERCULOSIS; TUBERCULOSIS VACCINES; VACCINATION; VACCINES, SUBUNIT; VACCINES, SYNTHETIC;

EID: 70449432815     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.09.111     Document Type: Review

References (41)

1. Martin C. The dream of a vaccine against tuberculosis; new vaccines improving or replacing BCG? Eur. Respir. J. 26(1), 162-167 (2005). (Pubitemid 40945945)
2. Hesseling AC, Marais BJ, Gie RP et al. The risk of disseminated bacille Calmette- Guérin (BCG) disease in HIV-infected children. Vaccine 25(1), 14-18 (2007).
3. Black GF, Weir RE, Floyd S et al. BCG-induced increase in interferon-γ response to mycobacterial antigens and efficacy of BCG vaccination in Malawi and the UK: two randomised controlled studies. Lancet 359(9315), 1393-1401 (2002). (Pubitemid 34442380)
4. McShane H. Vaccine strategies against tuberculosis. Swiss Med. Wkly 139(11-12), 156-160 (2009).
5. Andersen P, Doherty TM. The success and failure of BCG - implications for a novel tuberculosis vaccine. Nat. Rev. Microbiol. 3(8), 656-662 (2005). (Pubitemid 41052152)
6. Trunz BB, Fine P, Dye C. Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness. Lancet 367, 1173-1180 (2006).
7. Fifteen year follow up of trial of BCG vaccines in south India for tuberculosis prevention. Tuberculosis Research Centre (ICMR), Chennai, India. Indian J. Med. Res. 110, 56-69 (1999).
8. Behr MA, Small PM. Has BCG attenuated to impotence? Nature 389(6647), 133-134 (1997).
9. Lozes E, Denis O, Drowart A et al. Cross-reactive immune responses against Mycobacterium bovis BCG in mice infected with non-tuberculous mycobacteria belonging to the MAIS-Group. Scand. J. Immunol. 46(1), 16-26 (1997). (Pubitemid 27298859)
10. Brandt L, Feino Cunha J, Weinreich Olsen A et al. Failure of the Mycobacterium bovis BCG vaccine: some species of environmental mycobacteria block multiplication of BCG and induction of protective immunity to tuberculosis. Infect. Immun. 70(2), 672-678 (2002). (Pubitemid 34083827)
11. Buddle BM, Wards BJ, Aldwell FE, Collins DM, de Lisle GW. Influence of sensitisation to environmental mycobacteria on subsequent vaccination against bovine tuberculosis. Vaccine 20(7-8), 1126-1133 (2002).
12. Leung CC, Tam CM, Chan SL, Chan- Yeung M, Chan CK, Chang KC. Efficacy of the BCG revaccination programme in a cohort given BCG vaccination at birth in Hong Kong. Int. J. Tuberc. Lung Dis. 5(8), 717-723 (2001).
13. Kamala T, Paramasivan CN, Herbert D, Venkatesan P, Prabhakar R. Immune response and modulation of immune response induced in the guinea-pigs by Mycobacterium avium complex (MAC) and M. fortuitum complex isolates from different sources in the south Indian BCG trial area. Indian J. Med. Res. 103, 201-211 (1996). (Pubitemid 126450002)
14. McMurray DN. Recent progress in the development and testing of vaccines against human tuberculosis. Int. J. Parasitol. 33(5-6), 547-554 (2003).
15. Lin MY, Ottenhoff TH. Host-pathogen interactions in latent Mycobacterium tuberculosis infection: identification of new targets for tuberculosis intervention. Endocr. Metab. Immune Disord. Drug Targets 8(1), 15-29 (2008).
16. Brennan MJ. The tuberculosis vaccine challenge. Tubeculosis 85 (1-2), 7-12 (2005).
17. Horwitz MA, Harth G. A new vaccine against tuberculosis affords greater survival after challenge than the current vaccine in the guinea pig model of pulmonary tuberculosis. Infect. Immun. 71(4), 1672-1679 (2003). (Pubitemid 36368696)
18. Demangel C, Garnier T, Rosenkrands I, Cole ST. Differential effects of prior exposure to environmental mycobacteria on vaccination with Mycobacterium bovis BCG or a recombinant BCG strain expressing RD1 antigens. Infect. Immun. 73(4), 2190-2196 (2005). (Pubitemid 40470819)
19. Grode L, Seiler P, Baumann S et al. Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette- Guérin mutants that secrete listeriolysin. J. Clin. Invest. 115(9), 2472-2479 (2005). (Pubitemid 41266209)
20. Sun R, Skeiky YA, Izzo A et al. Novel recombinant BCG expressing perfringolysin O and the over-expression of key immunodominant antigens; preclinical characterization, safety and protection against challenge with Mycobacterium tuberculosis. Vaccine 27(33), 4412-4423 (2009).
21. Perez E, Samper S, Bordas Y, Guilhot C, Gicquel B, Martin C. An essential role for phoP in Mycobacterium tuberculosis virulence. Mol. Microbiol. 41(1), 179-187 (2001).
22. Martin C, Williams A, Hernandez- Pando R et al. The live Mycobacterium tuberculosis phoP mutant strain is more attenuated than BCG and confers protective immunity against tuberculosis in mice and guinea pigs. Vaccine 24(17), 3408-3419 (2006).
23. Sambandamurthy VK, Derrick SC, Hsu T et al. Mycobacterium tuberculosis δRD1 δpanCD: a safe and limited replicating mutant strain that protects immunocompetent and immunocompromised mice against experimental tuberculosis. Vaccine 24(37-39), 6309-6320 (2006). (Pubitemid 44247236)
24. Pinto R, Saunders BM, Camacho LR, Britton WJ, Gicquel B, Triccas JA. Mycobacterium tuberculosis defective in phthiocerol dimycocerosate translocation provides greater protective immunity against tuberculosis than the existing bacille Calmette-Guérin vaccine. J. Infect. Dis. 189(1), 105-112 (2004). (Pubitemid 38122336)
25. Hinchey J, Lee S, Jeon BY et al. Enhanced priming of adaptive immunity by a proapoptotic mutant of Mycobacterium tuberculosis. J. Clin. Invest. 117(8), 2279-2288 (2007).
26. Goonetilleke NP, McShane H, Hannan CM, Anderson RJ, Brookes RH, Hill AV. Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guérin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara. J. Immunol. 171(3), 1602-1609 (2003). (Pubitemid 36900097)
27. Brandt L, Skeiky YA, Alderson MR et al. The protective effect of the Mycobacterium bovis BCG vaccine is increased by coadministration with the Mycobacterium tuberculosis 72-kilodalton fusion polyprotein Mtb72F in M. tuberculosis-infected guinea pigs. Infect. Immun. 72(11), 6622-6632 (2004). (Pubitemid 39425445)
28. Elvang T, Christensen JP, Billeskov R et al. CD4 and CD8 T cell responses to the M. tuberculosis Ag85B-TB10.4 promoted by adjuvanted subunit, adenovector or heterologous prime boost vaccination. PLoS ONE 4(4), e5139 (2009).
29. Dietrich J, Andersen C, Rappuoli R, Doherty TM, Jensen CG, Andersen P. Mucosal administration of Ag85B-ESAT-6 protects against infection with Mycobacterium tuberculosis and boosts prior bacillus Calmette-Guérin immunity. J. Immunol. 177(9),6353-6360 (2006). (Pubitemid 44628854)
30. + memory T lymphocyte populations. Eur. J. Immunol. 37(11), 3089-3100 (2007).
31. Santosuosso M, McCormick S, Zhang X, Zganiacz A, Xing Z. Intranasal boosting with an adenovirus-vectored vaccine markedly enhances protection by parenteral Mycobacterium bovis BCG immunization against pulmonary tuberculosis. Infect. Immun. 74(8), 4634-4643 (2006). (Pubitemid 44157251)
32. Kalra M, Grover A, Mehta N et al. Supplementation with RD antigens enhances the protective efficacy of BCG in tuberculous mice. Clin. Immunol. 125(2), 173-183 (2007). (Pubitemid 47562899)
33. Lowrie DB, Tascon RE, Bonato VL et al. Therapy of tuberculosis in mice by DNA vaccination. Nature 400(6741), 269-271 (1999).
34. Taylor JL, Turner OC, Basaraba RJ, Belisle JT, Huygen K, Orme IM. Pulmonary necrosis resulting from DNA vaccination against tuberculosis. Infect. Immun. 71(4), 2192-2198 (2003). (Pubitemid 36368754)
35. Henao-Tamayo M, Palaniswamy GS, Smith EE et al. Post-exposure vaccination against Mycobacterium tuberculosis. Tuberculosis (Edinb.) 89(2), 142-148 (2009).
36. Giri PK, Verma I, Khuller GK. Adjunct immunotherapy with Ag85 complex proteins based subunit vaccine in a murine model of Mycobacterium tuberculosis infection. Immunotherapy 1, 31-37 (2009).
37. Sable SB, Kumar R, Kalra M et al. Peripheral blood and pleural fluid mononuclear cell responses to low-molecular- mass secretory polypeptides of Mycobacterium tuberculosis in human models of immunity to tuberculosis. Infect. Immun. 73(6), 3547-3558 (2005). (Pubitemid 40745899)
38. Cardona PJ, Amat I, Gordillo S et al. Immunotherapy with fragmented Mycobacterium tuberculosis cells increases the effectiveness of chemotherapy against a chronical infection in a murine model of tuberculosis. Vaccine 23(11), 1393-1398 (2005). (Pubitemid 40127332)
39. Stanford JL, Bahr GM, Rook GA et al. Immunotherapy with Mycobacterium vaccae as an adjunct to chemotherapy in the treatment of pulmonary tuberculosis. Tubercle 71(2), 87-93 (1990).
40. Global tuberculosis control - surveillance, planning, financing. WHO Geneva, Switzerland (2007) www.who.int/tb/publications/global- report/2007/download-centre/en/ index.html
41. AERAS. Global TB Vaccine Foundation www.aeras.or